New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

Gene Kinney Biography and Net Worth

Pres of Prothena

Dr. Kinney has served as our President and CEO since September 2016. Prior to being appointed to this position he was Chief Operating Officer and Chief Scientific Officer. Dr. Kinney is a member of Prothena’s founding leadership team, and between 2012 and 2016 held the position of Chief Scientific Officer and Head of Research and Development. Before joining Prothena, Dr. Kinney held positions with Elan Pharmaceuticals Inc., including Senior Vice President of Pharmacological Sciences (a position he held from 2011 to 2012), and Vice President, Pharmacology (a position he held from 2009 to 2011); while in those positions, Dr. Kinney also served as Head of Nonclinical Research for Janssen Alzheimer Immunotherapy. Before joining Elan, Dr. Kinney held several senior positions at Merck Research Laboratories and Bristol-Myers Squibb, and was an Assistant Professor at the Emory University School of Medicine. Dr. Kinney earned his B.A. from Bloomsburg University and his M.A. and Ph.D. from Florida Atlantic University. Dr. Kinney has served on our Board since September 2016.

How old is Gene G. Kinney?: Dr. Kinney is currently 55 years old. There are 7 older executives and no younger executives at Prothena. The oldest executive at Prothena is Ms. Carol D. Karp, Chief Regulatory Officer, who is 71 years old. Learn More on Gene G. Kinney's age.
How do I contact Gene G. Kinney?: The corporate mailing address for Dr. Kinney and other Prothena executives is 77 SIR JOHN ROGERSON`S QUAY BLOCK C GRAND CANAL DOCKLANDS, DUBLIN 2 L2, D02 T804. Prothena can also be reached via phone at (531) 236-2500 and via email at [email protected]. Learn More on Gene G. Kinney's contact information.
Has Gene G. Kinney been buying or selling shares of Prothena?: Gene G. Kinney has not been actively trading shares of Prothena during the last ninety days. Learn More on Gene G. Kinney's trading history.
Who are Prothena's active insiders?: Prothena's insider roster includes Christopher Henney (Director), Carol Karp (Insider), Gene Kinney (Pres), Michael Malecek (Insider), Tran Nguyen (CFO & Chief Strategy Officer ), Dennis Selkoe (Director), Karin Walker (CAO), and Wagner Zago (Insider). Learn More on Prothena's active insiders.
Are insiders buying or selling shares of Prothena?: During the last twelve months, insiders at the biotechnology company sold shares 34 times. They sold a total of 312,333 shares worth more than $20,586,952.52. The most recent insider tranaction occured on January, 24th when CAO Karin L. Walker sold 5,000 shares worth more than $170,000.00. Insiders at Prothena own 28.2% of the company. Learn More about insider trades at Prothena.
Information on this page was last updated on 1/24/2024.

Gene G. Kinney Insider Trading History at Prothena

Gene G. Kinney Buying and Selling Activity at Prothena

Prothena Company Overview

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland.

Today's Range

Now: $20.57

$20.44

$21.26

50 Day Range

MA: $26.09

$20.57

$30.30

2 Week Range

Now: $20.57

$20.44

$79.65

Volume

567,688 shs

Average Volume

774,167 shs

Market Capitalization

$1.11 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.21